Home » Newsletters » BioWorld

BioWorld

April 18, 2011

View Archived Issues

Academia-Fueled R&D Helps Gilead's Move into Oncology

Money Raised Year to Date

Money Raised By Biotech in 2011

Week in Review

Word on the Street

Week in Washington

FDA Approvals in March

Phase I Clinical Trials Update: March 2011

Phase II Clinical Trials Update: March 2011

Phase III Clinical Trials Update: March 2011

Non-U.S. Clinical Trials & Regulatory Actions: March 2011

FDA Submissions, Approvals & Other Actions: March 2011

Stock Gainers and Losers For The Week

BioWorld Stock Report For Public Biotechnology Companies

Big Rewards, Bigger Risks? The Truth About Antibodies

It's no secret that monoclonal antibodies (mAbs) have been hot biotech property for a while. Read More

IPO Pricing, Shares Offered: It's a Numbers Game

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 21, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 21, 2026.
Cell/gene therapy sector now sustainable; China competition mounting
BioWorld
There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...
Abbvie snags PD-1/VEGF bispecific in potential $5B Remegen deal
BioWorld
With rumors regarding a couple of potential mega-mergers making the rounds, the week of the annual J.P. Morgan Healthcare Conference kicked off with the official...
Neurotrimin unveiled as marker in intellectual disability
BioWorld Science
Neurotrimin (NTM) is a member of the IgLON family, the disruption of which has been tied to emotional learning deficits and anxiety-like behavior in animal...